Morfini M - Search Results

1

Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH.

Ragni MV, Croteau SE, Morfini M, Cnossen MH, Iorio A; Subcommittee on Factor VIII, Factor IX, and Rare Bleeding Disorders. Ragni MV, et al. Among authors: morfini m. J Thromb Haemost. 2018 Jul;16(7):1437-1441. doi: 10.1111/jth.14153. Epub 2018 Jun 5. J Thromb Haemost. 2018. PMID: 29762905 Free article. Review.

2

Pharmacokinetics of plasma-derived vs. recombinant FVIII concentrates: a comparative study.

Morfini M, Marchesini E, Paladino E, Santoro C, Zanon E, Iorio A. Morfini M, et al. Haemophilia. 2015 Mar;21(2):204-209. doi: 10.1111/hae.12550. Epub 2014 Oct 2. Haemophilia. 2015. PMID: 25274155 Clinical Trial.

3

A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease.

Peyvandi F, Castaman G, Gresele P, De Cristofaro R, Schinco P, Bertomoro A, Morfini M, Gamba G, Barillari G, Jiménez-Yuste V, Königs C, Iorio A, Federici AB. Peyvandi F, et al. Among authors: morfini m. Blood Transfus. 2019 Sep;17(5):391-398. doi: 10.2450/2019.0183-18. Epub 2019 Feb 4. Blood Transfus. 2019. PMID: 30747707 Free PMC article. Clinical Trial.

4

Comparative evaluation of the pharmacokinetics of three monoclonal factor VIII concentrates.

Morfini M, Mannucci PM, Longo G, Cinotti S, Messori A. Morfini M, et al. Thromb Res. 1991 Feb 1;61(3):285-90. doi: 10.1016/0049-3848(91)90105-6. Thromb Res. 1991. PMID: 1902997 Clinical Trial.

5

Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B.

Zhang Y, Roberts J, Bensen-Kennedy D, Jacobs I, Santagostino E, Voigt C, Feussner A, Morfini M, Sidhu J. Zhang Y, et al. Among authors: morfini m. J Thromb Haemost. 2016 Nov;14(11):2132-2140. doi: 10.1111/jth.13444. Epub 2016 Oct 3. J Thromb Haemost. 2016. PMID: 27513989 Free article. Clinical Trial.

6

Pharmacokinetic properties of recombinant factor VIII compared with a monoclonally purified concentrate (Hemofil M). The Recombinate Study Group.

Morfini M, Longo G, Messori A, Lee M, White G, Mannucci P. Morfini M, et al. Thromb Haemost. 1992 Oct 5;68(4):433-5. Thromb Haemost. 1992. PMID: 1448776 Clinical Trial.

7

A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards.

Morfini M, Cinotti S, Bellatreccia A, Paladino E, Gringeri A, Mannucci PM; ReFacto-AICE Study Group. Morfini M, et al. J Thromb Haemost. 2003 Nov;1(11):2283-9. doi: 10.1046/j.1538-7836.2003.00481.x. J Thromb Haemost. 2003. PMID: 14629459 Free article.

8

Pharmacokinetics of monoclonally-purified and recombinant factor VIII in patients with severe von Willebrand disease.

Morfini M, Mannucci PM, Tenconi PM, Longo G, Mazzucconi MG, Rodeghiero F, Ciavarella N, De Rosa V, Arter A. Morfini M, et al. Thromb Haemost. 1993 Aug 2;70(2):270-2. Thromb Haemost. 1993. PMID: 8236134

9

Factor VIII pharmacokinetics: intermittent infusion versus continuous infusion.

Morfini M, Messori A, Longo G. Morfini M, et al. Blood Coagul Fibrinolysis. 1996 Mar;7 Suppl 1:S11-4. Blood Coagul Fibrinolysis. 1996. PMID: 8735791 Review.

10

Pharmacokinetics of two pasteurized factor VIII concentrates by different and multicenter assays of factor VIII activity.

Messori A, Morfini M, Blomback M, Cinotti S, Longo G, Schimpf K, Schumacher K, Novakova-Banet A, Delvos U, Kjellman H. Messori A, et al. Among authors: morfini m. Thromb Res. 1992 Mar 15;65(6):699-708. doi: 10.1016/0049-3848(92)90109-n. Thromb Res. 1992. PMID: 1636162 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

271 results

Search Page